AEON Biopharma, Inc. (AEON) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. AEON Biopharma, Inc. is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® for therapeutic indications. Following the discontinuation of Phase 2 migraine trials in May 2024, the Company pivoted to a Section 351(k) biosimilar regulatory pathway. The Company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of August 7, 2025, there were 11,643,786 shares of Class A common stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net (Loss) Income | $(6.6) million | $2.5 million | $46.1 million |
| Operating Expenses | $4.3 million | $4.8 million | $(79.3) million* |
| Cash and Equivalents | $8.4 million | $8.4 million | $3.4 million |
| Accumulated Deficit | $(429.1) million | $(429.1) million | $(427.5) million |
| Convertible Notes (Fair Value) | $15.2 million | $15.2 million | $13.3 million |
| Warrant Liability | $2.1 million | $2.1 million | $1.5 million |
*Note: 2024 operating expenses include a $161.2 million gain from the change in fair value of contingent consideration, resulting in negative total operating costs.
Material Changes vs. Prior Period
- Operating Expenses: Cash-based operating expenses (SG&A and R&D) decreased significantly year-over-year. R&D expenses dropped 81% YTD to $1.9 million due to the wind-down of Phase 2 clinical trials for migraine and cervical dystonia. SG&A expenses decreased 20% YTD to $6.4 million due to headcount reductions and lower legal fees.
- Net Income Volatility: While the Company reported a net loss of $6.6 million for Q2 2025, it reported net income of $2.5 million for the six months ended June 30, 2025. This income is primarily driven by a non-cash gain of $86.2 million from the change in fair value of warrant liabilities, partially offset by a $75.6 million loss on the issuance of warrants in Q1 2025. In contrast, 2024 net income was driven by a $97.5 million gain on contingent consideration.
- Liquidity: Cash balances increased from $13,000 at year-end 2024 to $8.4 million at June 30, 2025, primarily due to $18.3 million in net proceeds from a public offering in January 2025 and $0.2 million from an at-the-market (ATM) offering.
- Capital Structure: The Company executed a 1-for-72 reverse stock split in February 2025. Additionally, significant cashless warrant exercises occurred, increasing the share count from ~555,000 at the start of 2025 to ~11.5 million by June 30, 2025.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern. The Company expects to have sufficient cash to fund operations only into the fourth quarter of 2025. Additional financing is required to continue development.
- Regulatory Pathway: The Company is pursuing a Section 351(k) biosimilar pathway for ABP-450 using BOTOX as the reference product. Analytical studies are underway, with results expected in Q3 2025. A Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA is expected in Q4 2025.
- Listing Compliance: The Company received a notice of non-compliance from NYSE American regarding stockholders' equity requirements. A plan to regain compliance was accepted, granting the Company until August 3, 2026, to meet the standards. Failure to comply could result in delisting.
- Legal Proceedings: A lawsuit filed by Odeon Capital Group LLC regarding a deferred underwriting fee of $1.25 million is proceeding to trial. The Company successfully dismissed non-breach claims in April 2024.
- Internal Controls: The Company identified material weaknesses in internal control over financial reporting related to risk assessment of complex transactions and segregation of duties. Remediation efforts are ongoing.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash exhaustion (stated as Q4 2025) and the status of any new financing discussions.
- Warrant Liability Volatility: Review the impact of stock price fluctuations on the warrant liability, which caused significant non-cash gains/losses in the P&L.
- NYSE Compliance: Monitor progress on the plan to regain compliance with NYSE American stockholders' equity requirements by August 2026.
- Daewoong Agreement: Assess the risks associated with the exclusive supply agreement with Daewoong, including the "Termination Purchase Right" if commercialization or clinical advancement ceases.
- Internal Control Remediation: Confirm the timeline for remediation of material weaknesses in financial reporting controls.